Advertisement

Topics

Latest "Inotrem" News Stories

18:18 EST 19th February 2019 | BioPortfolio

Here are the most relevant search results for "Inotrem" found in our extensive news archives from over 250 global news sources.

More Information about Inotrem on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Inotrem for you to read. Along with our medical data and news we also list Inotrem Clinical Trials, which are updated daily. BioPortfolio also has a large database of Inotrem Companies for you to search.

Showing "Inotrem" News Articles, all 7

Friday 1st February 2019

Inotrem gains rights to TREM1 biomarker for cardiovascular diseases


Thursday 31st January 2019

Inotrem Announces an Extension of Its License Agreement for the Biomarker Soluble TREM-1 to Cardiovascular Diseases

Inotrem S.A., a biotechnology company focused on the modulation of the TREM-1 pathway for the management of acute and chronic inflammatory syndromes, announced today the signature of an exclusive license agreement with four major research organizations, under which it receives the exclusive worldwide rights for the biomarker soluble TREM-1 (sTREM-1) in car...

Thursday 11th October 2018

Inotrem reports 'favorable' markers for septic shock candidate


Tuesday 2nd October 2018

Septic Shock Drug Shows Promise for Personalized Medicine

Septic shock may no longer be as shocking in the future, as a Phase IIa trial brings hope for a personalized immunomodulatory treatment from the French biotech Inotrem.   In sepsis, the immune system overreacts to the infection of a ... The post Septic Shock Drug Shows Promise for Personalized Medicine appeared first on Labiotech.eu.

Monday 1st October 2018

Inotrem reports positive data from Phase IIa trial of nangibotide

Inotrem has reported positive results from a Phase IIa trial of nangibotide (LR12) for the treatment of septic shock patients....Read More... The post Inotrem reports positive data from Phase IIa trial of nangibotide appeared first on Drug Development Technology.

Inotrem’s nangibotide yields positive results in septic shock phase IIa study

The results were presented today at the annual congress of the International Sepsis Forum in Bangkok. Septic shock is the ultimate complication of sepsis and currently constitutes an The post Inotrem’s nangibotide yields positive results in septic shock phase IIa study appeared first on Pharma Business review.

Sunday 30th September 2018

Inotrem Announces Positive Results From the Phase IIa Study of Its Lead Compound, Nangibotide (LR12), in the Treatment of Septic Shock

The study demonstrated the safety and tolerability of its lead compound in patients suffering from septic shock Inotrem S.A., a biotechnology focused on the modulation of the TREM pathway for the management of inflammatory syndromes, announced positive results for its Phase IIa study that demonstrated the safety and tolerability of it...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks